Literature DB >> 25145424

Promising new developments in cervical cancer.

Mary McCormack, Francesca Lake.   

Abstract

Mary McCormack* speaks to Francesca Lake, Managing Commissioning Editor: Dr McCormack qualified as a doctor from Guy's and St Thomas's Hospital (London, UK) in 1993. She has worked in a variety of London cancer centers and was appointed as a consultant at University College London Hospitals (London, UK) in 2002. She is a clinical oncologist, offering chemotherapy and radiotherapy for gynecological and breast cancers. She is a member of the National Cancer Research Institute Gynecological Clinical Studies Group and the Gynecologic Cancer InterGroup, and is a major contributor to national and international clinical trials. She is also a medical advisor to Jo's Trust and a founding member of Debbie Fund, a University College London-based charity dedicated to raising funds for cervical cancer research.

Entities:  

Keywords:  INTERLACE; bevacizumab; cervical cancer; relapsed disease; research

Mesh:

Year:  2014        PMID: 25145424     DOI: 10.2217/fon.14.63

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  1 in total

1.  From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.

Authors:  Charlotte Ngo; Sanne Samuels; Ksenia Bagrintseva; Andrea Slocker; Philippe Hupé; Gemma Kenter; Marina Popovic; Nina Samet; Patricia Tresca; Heiko von der Leyen; Eric Deutsch; Roman Rouzier; Lisa Belin; Maud Kamal; Suzy Scholl
Journal:  BMC Cancer       Date:  2015-11-04       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.